Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon

被引:24
|
作者
Scaioli, Eleonora [1 ]
Colecchia, Antonio [1 ]
Marasco, Giovanni [1 ]
Schiumerini, Ramona [1 ]
Festi, Davide [1 ]
机构
[1] Univ Bologna, Policlin S Orsola, Dept Med & Surg Sci, Via Massarenti 9, I-40138 Bologna, Italy
关键词
Diverticular disease; Gut microbiota; Low-grade inflammation; Mesalazine; Probiotics; HIGH-FIBER DIET; DOUBLE-BLIND; MAINTAINING REMISSION; INTERSTITIAL-CELLS; RIFAXIMIN; MESALAZINE; EFFICACY; PROBIOTICS; MECHANISMS; PREVENTION;
D O I
10.1007/s10620-015-3925-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Colonic diverticulosis imposes a significant burden on industrialized societies. The current accepted causes of diverticula formation include low fiber content in the western diet with decreased intestinal content and size of the lumen, leading to the transmission of muscular contraction pressure to the wall of the colon, inducing the formation of diverticula usually at the weakest point of the wall where penetration of the blood vessels occurs. Approximately 20 % of the patients with colonic diverticulosis develop abdominal symptoms (i.e., abdominal pain and discomfort, bloating, constipation, and diarrhea), a condition which is defined as symptomatic uncomplicated diverticular disease (SUDD). The pathogenesis of SUDD symptoms remains uncertain and even less is known about how to adequately manage bowel symptoms. Recently, low-grade inflammation, altered intestinal microbiota, visceral hypersensitivity, and abnormal colonic motility have been identified as factors leading to symptom development, thus changing and improving the therapeutic approach. In this review, a comprehensive search of the literature regarding on SUDD pathogenetic hypotheses and pharmacological strategies was carried out. The pathogenesis of SUDD, although not completely clarified, seems to be related to an interaction between colonic microbiota alterations, and immune, enteric nerve, and muscular system dysfunction (Cuomo et al. in United Eur Gastroenterol J 2:413-442, 2014). Greater understanding of the inflammatory pathways and gut microbiota composition in subjects affected by SUDD has increased therapeutic options, including the use of gut-directed antibiotics, mesalazine, and probiotics (Bianchi et al. in Aliment Pharmacol Ther 33:902-910, 2011; Comparato et al. in Dig Dis Sci 52:2934-2941, 2007; Tursi et al. in Aliment Pharmacol Ther 38:741-751, 2013); however, more research is necessary to validate the safety, effectiveness, and cost-effectiveness of these interventions.
引用
收藏
页码:673 / 683
页数:11
相关论文
共 50 条
  • [21] IMPACT OF TREATMENTS ON FECAL MICROBIOTA AND FECAL METABOLOME IN SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE OF THE COLON: A PILOT STUDY
    Laghi, L.
    Mastromarino, P.
    Elisei, W.
    Capobianco, D.
    Zhu, C-L
    Picchio, M.
    Giorgetti, G.
    Brandimarte, G.
    Tursi, A.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2018, 32 (06) : 1421 - 1432
  • [22] Continuous Versus Cyclic Mesalazine Therapy for Patients Affected by Recurrent Symptomatic Uncomplicated Diverticular Disease of the Colon
    Antonio Tursi
    Giovanni Brandimarte
    Gian Marco Giorgetti
    Walter Elisei
    Digestive Diseases and Sciences, 2007, 52 : 671 - 674
  • [23] Symptomatic Uncomplicated Diverticular Disease: Evaluation of Mesalamine and/or Probiotics Treatment in Fecal Calprotectin
    Bafutto, Mauro
    Gomes Costa, Michelle Bafutto
    Ferreira Bafutto, Eduardo Henrique
    Ferreira Bafutto, Alexandre Augusto
    de Almeida, Jose Roberto
    de Oliveira, Enio Chaves
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2016, 50 : S108 - S108
  • [24] Quality of life in uncomplicated symptomatic diverticular disease: Is it another good reason for treatment?
    Comparato, Giuseppe
    Fanigliulo, Libera
    Aragona, Giovanni
    Cavestro, Giulia M.
    Cavallaro, Lucas G.
    Leandro, Gioacchino
    Pilotto, Alberto
    Nervi, Giorgio
    Soliani, Paolo
    Sianesi, Mario
    Franze, Angelo
    Di Mario, Francesco
    DIGESTIVE DISEASES, 2007, 25 (03) : 252 - 259
  • [25] New strategies for the management of diverticular disease: insights for the clinician
    Boynton, Wen
    Floch, Martin
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2013, 6 (03) : 205 - 213
  • [26] Efficacy of a New Nutraceutical Formulation in Patients with Symptomatic Uncomplicated Diverticular Disease (SUDD): a Prospective Observational Study
    D'Amico, Ferdinando
    Fiorini, Giulia
    Tursi, Antonio
    Saracino, Ilaria Maria
    Pavoni, Matteo
    Danese, Silvio
    Vaira, Dino
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2019, 28 : 49 - 52
  • [27] Irritable bowel syndrome and colonic diverticular disease: overlapping symptoms and overlapping therapeutic approaches
    Alamo, Rommel Zerpa
    Quigley, Eamonn M. M.
    CURRENT OPINION IN GASTROENTEROLOGY, 2019, 35 (01) : 27 - 33
  • [28] Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon
    Latella, G
    Pimpo, MT
    Sottili, S
    Zippi, M
    Viscido, A
    Chiaramonte, M
    Frieri, G
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2003, 18 (01) : 55 - 62
  • [29] General practitioners' management of symptomatic uncomplicated diverticular disease of the colon by using rifaximin, a non-adsorbable antibiotic
    De Bastiani, R.
    Sanna, G.
    Bertolusso, L.
    Casella, G.
    De Polo, M.
    Zamparella, M.
    Cottone, C.
    Tosetti, C.
    Mancuso, M.
    Pirrotta, E.
    Lanzarotto, L.
    Napoli, L.
    De Bastiani, M.
    Disclafani, G.
    Gambaro, P.
    Scoglio, R.
    Belvedere, A.
    Fasulo, S.
    D'Urso, M.
    Benedetto, E.
    Baldi, E.
    Marchesan, F.
    Abagnale, G.
    Turnava, L.
    Salome, E.
    Ingravalle, F.
    Tursi, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (01) : 423 - 430
  • [30] Ultrasonographic and Functional Features of Symptomatic Uncomplicated Diverticular Disease
    Maconi, Giovanni
    Dell'Era, Alessandra
    Flor, Nicola
    De Silvestri, Annalisa
    Lavazza, Alessandra
    Ardizzone, Sandro
    Bassotti, Gabrio
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2023, 14 (06)